Genzyme, now a Cambridge-based unit of the French drug giant Sanofi SA, said that regulators have given it approval to market a multiple sclerosis drug in the European Union. The drug is called Lemtrada, and it is one that Genzyme has high hopes for. Genzyme has a heritage in developing drugs for rare diseases.

Topics:  cambridge-based   french   sanofi sa   union   massachusetts   biogen idec   lemtrada   european   aubagio   genzyme ms   genzyme   ms   approval   drugs   multiple   market   sclerosis   
BING NEWS:
  • Sanofi settles dispute with Genzyme investors over MS drug
    As part of Sanofi’s $20 billion takeover of Genzyme, the French drugmaker promised shareholders in the US biotech payouts under a Contingent Value Right (CVR) that was due when MS drug Lemtrada ...
    11/3/2019 - 11:00 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News